Today’s podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. First, you will hear from Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, Catherine Diefenbach, MD, NYU Langone, New York, NY, and Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, who discuss novel combinations being explored in the frontline setting for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Sattva Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, will then give updates on the use of CAR T-cells in the relapsed/refractory (R/R) setting for NHL, including follicular lymphoma (FL) and DLBCL. This will be followed by Catherine Diefenbach, MD, NYU Langone, New York, NY, and Taylor Brooks, MD, Cleveland Clinic, Cleveland, OH, who discuss the use of bispecific antibodies, and Julio Chavez, MD, Moffitt Cancer Center, Tampa, FL, who shares data on CELMoDs under investigation for the treatment of FL and DLBCL. The post Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting appeared first on VJHemOnc.

This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. This episode focuses on updates in myelodysplastic syndromes (MDS). You will hear insights into managing anemia in lower-risk MDS (LR-MDS) from Sophie Park, MD, CHU Grenoble Alpes, Grenoble, France, Esther Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, and Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany. They share data from the EPO-Pretar trial (NCT03223961), which is investigating early versus late onset of epoetin alfa treatment, an analysis of patient-reported outcomes in the COMMANDS trial (NCT03682536), and the effect of prior therapies on the activity of imetelstat in the IMerge trial (NCT02598661). Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, and Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, then go on to discuss novel approaches to managing higher-risk MDS (HR-MDS), including an individualized allogeneic stem cell transplantation (alloSCT) approach and novel non-transplant treatment approaches. The post Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS appeared first on VJHemOnc.

Explore groundbreaking insights from the latest American Society of Hematology Meeting! Experts discuss the promising efficacy and safety of BTK inhibitors like pirtobrutinib and acalabrutinib in treating chronic lymphocytic leukemia. Investigational BTK degraders NX2127 and NX5948 show remarkable response rates. Discover innovative therapies including bispecific antibodies and the BCL2 inhibitor sonrotoclax, which are paving new paths for treatment. The dialogue reveals the potential for significant improvements in patient outcomes!

In this insightful discussion, Dr. Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center shares his expertise on treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). He dives into the challenges of managing this rare cancer and reviews current therapies like tagraxofusp. The conversation also covers patient eligibility, the role of stem cell transplants, and emerging treatments targeting CD123. Dr. Pemmaraju highlights ongoing clinical trials that promise to advance treatment strategies and improve outcomes for BPDCN patients.

Discover innovative strategies for pain management in patients with sickle cell disease and the transformative Universal Care Plan initiative. Learn about the Sickle Eye Project, which aims to tackle visual impairments linked to the condition. Uncover the critical healthcare gaps in sub-Saharan Africa, such as the need for newborn screening. The podcast also emphasizes the psychosocial needs of patients, advocating for integrated mental health services to support their emotional well-being.

Expert guests Marlise Luskin, a hematology specialist, Nicole LeBoeuf, a dermatologist, and hematologist Shai Shimony from Dana-Farber Cancer Institute discuss blastic plasmacytoid dendritic cell neoplasm (BPDCN). They delve into its unique symptoms, including deep purple skin lesions, diagnostic challenges, and the necessity of a multidisciplinary approach. The conversation also highlights treatment options like tagraxofusp and venetoclax, advancements in targeted therapies, and the critical role of collaboration among healthcare professionals to improve outcomes for patients.

Dr. Monique Minnema from University Medical Center Utrecht, a specialist in Bing-Neel syndrome, joins the discussion on managing complications of Waldenström’s macroglobulinemia. Key topics include the challenges in diagnosing Bing-Neel syndrome and the potential of treatments like rituximab and ibrutinib. The conversation also touches on the link between acquired von Willebrand disease and WM, emphasizing the risks of bleeding complications, and highlights the importance of monitoring and new strategies for patient care.

Krina Patel, an expert in CAR T-cell therapies at MD Anderson Cancer Center, dives into the cutting-edge treatments for high-risk multiple myeloma. She discusses the latest clinical trial findings and how CAR-T therapies are tailored for specific high-risk subgroups. The conversation also touches on the potential of allogeneic CAR T-cell products. Additionally, there’s a focus on bispecific antibodies, with insights on resistance mechanisms and combination strategies that may enhance treatment efficacy. This is an enlightening listen for cancer care innovators!

Marina Konopleva is the Director of Leukemia at Montefiore Cancer Center, while Emma Groarke is an Associate Research Physician at the NIH. They delve into the landscape of rare myeloid diseases like BPDCN, CMML, and VEXAS, discussing innovative therapies including Tagrexofaspa and IDH inhibitors. The conversation highlights the complexities in treatment due to patient variability and the significance of risk stratification in decision-making. They also emphasize the importance of collaborative research to enhance outcomes in these challenging conditions.

Join experts Krish Patel, MD, specializing in mantle cell lymphoma treatment, Marek Trněný, MD, PhD, a key contributor to BTK inhibitor trials, and Michael Wang, MD, who offers insights on therapeutic sequencing. They delve into groundbreaking trials like ECHO and SHINE, discussing the role of BTK inhibitors and their effectiveness for older patients. Notably, they address optimal sequencing methods to prevent cross-resistance and strategies for managing cardiac toxicities. Their collaboration underscores a comprehensive approach to enhancing patient care.